Related Experiment Video
Updated: Aug 20, 2026
An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles
Published on: March 18, 2015
Gallium compounds as antineoplastic agents
1Division of Neoplastic Diseases, Department of Medicine, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226, USA. chitambr@mcw.edu
Purpose Of Review:
The purpose of this review is to provide an outline of the basic and clinical information on gallium nitrate as an antineoplastic agent. Although early clinical trials indicated that gallium nitrate had activity against lymphoma and bladder cancer, its subsequent development centered primarily on its effect on bone metabolism and not on its antineoplastic activity. As a result, the drug was approved for the treatment of hypercalcemia of malignancy. However, pharmaceutical production of gallium nitrate ceased during the late 1990s, bringing several gallium-based clinical trials to a halt. Gallium nitrate has recently become commercially available, thus reopening the door for clinical trials evaluating it as an antineoplastic agent.
Recent Findings:
Multicenter clinical trials have recently been conducted to reevaluate gallium nitrate for the treatment of lymphoma. An oral formulation of gallium is also in development. Gallium's mechanisms of action include its binding to transferrin, targeting to transferrin receptors on lymphoma cells, and inhibiting ribonucleotide reductase. Recent investigations show that gallium activates caspases and induces apoptosis through the mitochondrial pathway, whereas complementary DNA microarray studies suggest that changes in intracellular trafficking pathways may be important in gallium resistance.
Summary:
Gallium nitrate has demonstrated activity against lymphoma and bladder cancer, which is likely the result of selective targeting of these malignancies. An important property of gallium nitrate is that it is not myelosuppressive and it lacks cross-resistance to other drugs. Further investigations are needed to understand better its molecular targets and to determine its clinical efficacy in combination with other drugs.
Insights
Gallium nitrate shows promise as an antineoplastic agent, particularly for lymphoma and bladder cancer. Its unique mechanisms and lack of myelosuppression warrant further clinical investigation.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Gallium nitrate was initially investigated for antineoplastic properties against lymphoma and bladder cancer.
- Development shifted to bone metabolism, leading to its approval for hypercalcemia of malignancy.
- Recent commercial availability has revived interest in gallium nitrate's anticancer potential.
Purpose of the Study:
- To review basic and clinical information on gallium nitrate as an antineoplastic agent.
- To highlight recent findings and future directions for gallium nitrate in cancer treatment.
- To reevaluate gallium nitrate's efficacy, especially for lymphoma.
Main Methods:
- Review of existing clinical trials and scientific literature.
- Analysis of gallium nitrate's mechanisms of action, including transferrin binding and enzyme inhibition.
- Examination of recent investigations into apoptosis induction and resistance pathways.
Main Results:
- Gallium nitrate demonstrated activity against lymphoma and bladder cancer, suggesting selective targeting.
- Mechanisms involve transferrin receptor targeting, ribonucleotide reductase inhibition, and apoptosis induction.
- Gallium nitrate is not myelosuppressive and shows no cross-resistance with other chemotherapy drugs.
Conclusions:
- Gallium nitrate exhibits promising antineoplastic activity, particularly against lymphoma and bladder cancer.
- Its non-myelosuppressive nature and lack of cross-resistance are significant advantages.
- Further research is crucial to elucidate molecular targets and optimize combination therapies.
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
